New Monoclonal Antibody Products to Boost Advanced Drug Delivery Market

08 Apr 2011 • by Natalie Aster

New Monoclonal Antibody Products to Boost Advanced Drug Delivery Market

New York - An array of new monoclonal antibody products will enter the market in coming years, driving growth in the $60.6 billion global market for advanced drug delivery systems, according to the report “Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies)” by Kalorama Information.

“Monoclonal antibodies represent one of the largest classes of biotechnological drugs being developed,” said Bruce Carlson, publisher of Kalorama Information. “Several products are currently on the market and many more are expected within the next few years.”

Monoclonals are special antibodies designed to bind to a particular substance, such as a cancerous cell, which they can then detect and even treat. The first monoclonal antibody, Rituxan (Biogen IDEC), received approval in November 1997. The product is indicated for the treatment of relapsed or refractory, low-grade or follicular B-cell non-Hodgkin’s lymphomas. In 1998, Centocor launched Remicade for the treatment of colorectal cancer. The product was combined with methotrexate and was subsequently approved to treat rheumatoid arthritis and Crohn’s disease. Since then many products have appeared on the marketplace; for instance, MedImmune offers Synagis, a humanized monoclonal antibody that prevents the serious lower respiratory tract disease in infants caused by respiratory syncytial virus. According to Kalorama, growth has slowed in recent years, but these products are still leading growth in biopharmaceuticals.

Report Details:

Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies)
Published: December 2010
Pages: 170
Price: US$ 3,995

“While you won’t see the double digit growth that you saw in past years in this area, monoclonal antibodies remain an important part of this multi-billion dollar market,” said Bruce Carlson, publisher of Kalorama Information.“There are a multitude of new products.” Kalorama’s report lists over 25 products that are in Phase III and over 70 in development targeting a range of diseases such as MS, Alzheimer’s, asthma, and various forms of cancer.

According to Kalorama, Roche is the clear leader in the market. The company is involved in the marketing and distribution of five of the top monoclonal antibodies on the market—Avastin, Herceptin, Lucentis, Rituxan and Xolair. And the company has at least four significant monoclonal products in development. However, Kalorama notes that competitors are actively trying to improve market share in the future and the market could look very different a few years from now. Abbott, Pfizer and Novartis are among the companies with monoclonal products in development.

More information can be found in the report “Advanced Drug Delivery Markets (Liposomes, Polymers and Monoclonal Antibodies)” by Kalorama Information. The report analyzes several trends, including molecular imprinted polymers, antibiotic biodegradable implants, hot-melt extrusion technology, sorbent technology, and gene therapy drug delivery. It concentrates on liposome and polymer drug delivery, as well as monoclonal antibodies.

To order the report or ask for sample pages contact ps@marketpublishers.com

CONTACTS

The Market Publishers, Ltd.
Mrs. Alla Martin
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
www.marketpublishers.com